<DOC>
	<DOCNO>NCT00110942</DOCNO>
	<brief_summary>The purpose study evaluate clinical benefit ( change Western Ontario McMaster University Osteoarthritis Index [ WOMAC ] pain score ) AMG 108 ( 300 mg subcutaneously [ SC ] every 4 week ) subject OA .</brief_summary>
	<brief_title>Treatment Patients With Osteoarthritis ( OA )</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Diagnosed knee OA determine American College Rheumatology ( ACR ) criterion Pain define level great equal 30 mm 100 mm Visual Analogue Scale ( VAS ) If currently take counter nutritional supplement , must stable dos great 2 month prior screen If utilizing physical therapy , biomechanical device orthotic support , must use treatment device great equal 2 month prior screen If currently previously take nonprescribed supplement ( e.g. , glucosamine chondroitin sulphate , shark cartilage , diacerein , soya extract , etc . ) must stable dos least 2 month prior screen If currently take nonsteroidal antiinflammatory drug ( NSAIDs ) , must stable dos least 2 month prior screen Able discontinue NSAIDs least 5 halflives ( approximately 3 day ) prior Day 1 Radiographic evidence tibiofemoral compartment knee OA within 12 month screen Signed write informed consent Malignancy within previous 5 year , except basal cell situ cancer Significant hematologic disease Active infection history recurrent chronic infection Known diagnosis HIV , hepatitis B , hepatitis C infection Uncontrolled diabetes cardiovascular disease hypertension Inflammatory arthropathy include secondary OA Isolated OA patellofemoral joint ( bi tricompartmental involvement exclusion ) Endstage ( `` boneonbone '' ) OA ( Kellgren Lawrence score 4 ) OA hip ipsilateral index knee Total white cell count le 2.0 x 10^9/L and/or platelet count le 100 x 10^9/L observe within 1 month precede screen Prior intraarticular ( IA ) injection anakinra experimental interleukin1 ( IL1 ) inhibitor therapy Concurrent treatment SC anakinra Concurrent recent ( less equal 1 month ) use experimental therapy Prior IA corticosteroid injection within 1 month study Prior viscosupplement therapy within 3 month study Contraindication ( ) IA injection Subjects pregnant breastfeeding , plan become pregnant study Subject use adequate contraception Known allergy E coliderived product Unable understand inform consent Concerns regard subject 's compliance protocol procedure Subject available followup assessment Active substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Intra-articular</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>OA</keyword>
	<keyword>anakinra</keyword>
	<keyword>Amgen</keyword>
</DOC>